Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
The product does NOT contain any epitope tags. The protein has a calculated MW of 14.5 kDa. The protein migrates as 18-28 kDa on a SDS-PAGE gel under reducing (R) condition due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Biotinylated Human GM-CSF, epitope tag free, primary amine labeling on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Biotinylated Human GM-CSF, epitope tag free, primary amine labeling (Cat. No. GMF-H8214) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.2 μg/well) plate can bind Human GM-CSF R alpha, Fc Tag (Cat. No. GRA-H5255) with a linear range of 1-8 ng/mL (Routinely tested).
Loaded Biotinylated Human GM-CSF, epitope tag free, primary amine labeling (Cat. No. GMF-H8214) on SA Biosensor, can bind Human GM-CSF R alpha, His Tag (SPR verified) (Cat. No. GRA-H52H7) with an affinity constant of 23.1 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To support ADC research, we offer a comprehensive range of products and services covering early discovery, CMC quality control, and both preclinical and clinical development. Our solutions help researchers accelerate innovation and optimize ADC design for maximum therapeutic impact.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Otilimab | MOR-04357; GSK-3196165; GSK-165; MOR-103 | Phase 3 Clinical | University Of Melbourne | Stomach Neoplasms; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Spondylarthritis; Multiple Sclerosis; Severe Acute Respiratory Syndrome; Osteoarthritis | Details |
Plonmarlimab | TJM-2; TJ-003234; TJ-003234RAR101 | Phase 3 Clinical | I-Mab Biopharma Co Ltd | Macrophage Activation Syndrome; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Arthritis, Gouty; Lymphohistiocytosis, Hemophagocytic | Details |
Pexastimogene devacirepvec | TG-6006; JX-594 | Phase 3 Clinical | Sillajen Inc, Regeneron Pharmaceuticals Inc, National Cancer Institute, Samsung Medical Center & Samsung Electronics Devices Llc | Sarcoma; Neoplasm Metastasis; Melanoma; Carcinoma, Hepatocellular; Lymphoma; Lung Neoplasms; Colorectal Neoplasms; Sarcoma, Ewing; Neuroblastoma; Solid tumours; Breast Neoplasms; Wilms Tumor; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Rhabdomyosarcoma; Liver Neoplasms; Ovarian Neoplasms | Details |
Gemogenovatucel-T | IND-14205 | Phase 3 Clinical | Gradalis Inc | Liver Neoplasms; Ovarian Neoplasms; Colonic Neoplasms; Carcinoma, Ovarian Epithelial; Sarcoma, Ewing; Breast Neoplasms; Peritoneal Neoplasms; Uterine Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Namilumab | MT-203; AMG-203; IZN-101 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd, Amgen Inc | Non-radiographic axial spondyloarthritis; Arthritis, Rheumatoid; Sarcoidosis; Sarcoidosis, Pulmonary; Plaque psoriasis | Details |
PBI-1402 | PBI-1402 | Phase 2 Clinical | Prometic Life Sciences | Anemia | Details |
BT-001 | BT-001 | Phase 2 Clinical | Transgene Sa | Carcinoma, Merkel Cell; Neoplasms; Triple Negative Breast Neoplasms; Sarcoma; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
Breast cancer therapy (BriaCell Therapeutics) | Phase 2 Clinical | Briacell Therapeutics Corp | Breast Neoplasms; Metastatic breast cancer | Details | |
Gimsilumab | MORAb-022; KIN-1901 | Phase 2 Clinical | Morphotek Inc | Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Rheumatic Diseases; Inflammation | Details |
MEDI-5395 | MEDI-5395; MEDI5395 | Phase 1 Clinical | Medimmune | Solid tumours | Details |
This web search service is supported by Google Inc.